Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Drugs

• Publication date

  2000-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003495-200060040-00005PMID 11085200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of oxaliplatin in patients with advanced cancer

  2004cited by this paper
• Intracellular glutathione and cytotoxicity of platinum complexes

  2004cited by this paper
• Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

  2004cited by this paper
• Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

  2000influential reference
• Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.

  2000cited by this paper
• A phase I study of Docetaxel (D) and Oxaliplatin (L-OHP) as front-line treatment in metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC)

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

  2000influential reference
• Clinical pharmacokinetics of oxaliplatin: a critical review.

  2000influential reference
• Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.

  2000cited by this paper
• Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

  2000cited by this paper
• Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.

  2000cited by this paper
• Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000influential reference
• Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience.

  1999influential reference
• Where do we stand with 5-fluorouracil?

  1999cited by this paper
• Randomized phase II study of CPT-11 plus mitomycin C versus oxaliplatin plus mitomycin C in previously treated patients with advanced colorectal cancer (ACC)

  1999cited by this paper
• Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.

  1999influential reference
• Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.

  1999cited by this paper
• Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.

  1999influential reference
• Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

  1999cited by this paper
• Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials.

  1999cited by this paper
• Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines

  1999cited by this paper
• A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma

  1999influential reference
• Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.

  1999cited by this paper
• Treatment of refractory and recurrent ovarian cancer.

  1999cited by this paper
• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

  1999cited by this paper
• Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.

  1999cited by this paper
• Antitumour activity of oxaliplatin in neuroblastoma cell lines.

  1999cited by this paper
• Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.

  1999cited by this paper
• Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.

  1999cited by this paper
• More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.

  1999cited by this paper
• Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.

  1999cited by this paper
• Specificity of platinum-DNA adduct repair.

  1999cited by this paper
• Anaphylaxis after oxaliplatin.

  1999cited by this paper
• Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.

  1999influential reference
• Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques.

  1998cited by this paper
• Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.

  1998cited by this paper
• Oxaliplatin: a review of preclinical and clinical studies.

  1998influential reference
• Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

  1998cited by this paper
• Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.

  1998cited by this paper
• The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.

  1998cited by this paper
• Activity of oxaliplatin against human tumor colony-forming units.

  1998cited by this paper
• Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.

  1998cited by this paper
• Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.

  1998influential reference
• Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

  1998cited by this paper
• A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).

  1998cited by this paper
• Oxaliplatin: mechanism of action and antineoplastic activity.

  1998influential reference
• Severe anaphylactic reactions to oxaliplatin.

  1998cited by this paper
• Chemotherapy of advanced ovarian cancer.

  1998cited by this paper
• Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.

  1998cited by this paper
• Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.

  1998influential reference
• Oxaliplatin combined to 5‐fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer

  1998cited by this paper
• Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

  1998cited by this paper
• Chemotherapy of advanced ovarian cancer.

  1998cited by this paper
• Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)

  1998cited by this paper
• Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer

  1998cited by this paper
• Oxaliplatin in practice.

  1998cited by this paper
• Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.

  1997cited by this paper
• Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

  1997cited by this paper
• Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers

  1997influential reference
• Oxaliplatine, acide folinique et 5-fluorouracile (folfox) en seconde ligne thérapeutique du cancer colorectal métastasé

  1997cited by this paper
• Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.

  1997influential reference
• In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.

  1997cited by this paper
• Oxaliplatin, leucovorin and fluorouracil in pretreated patients with advanced colorectal cancer.

  1997cited by this paper
• Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

  1997influential reference
• [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].

  1997cited by this paper
• Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.

  1996influential reference
• Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  1996cited by this paper
• Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.

  1996cited by this paper
• Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line.

  1996cited by this paper
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

  1996influential reference
• The role of DNA mismatch repair in platinum drug resistance.

  1996cited by this paper
• Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.

  1996cited by this paper
• Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells.

  1996cited by this paper
• Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

  1996cited by this paper
• Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.

  1996cited by this paper
• Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

  1996influential reference
• Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.

  1995cited by this paper
• Comparative Adverse Effect Profiles of Platinum Drugs

  1995cited by this paper
• Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.

  1995cited by this paper
• A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.

  1995cited by this paper
• Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.

  1994influential reference
• Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.

  1994influential reference
• Factors influencing the natural history of colorectal liver metastases.

  1994influential reference
• Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.

  1993influential reference
• In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.

  1993influential reference
• Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.

  1993cited by this paper
• A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

  1992influential reference
• Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.

  1992cited by this paper
• Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.

  1992cited by this paper
• Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.

  1991cited by this paper
• Cisplatin/carboplatin cross-resistance in ovarian cancer.

  1989cited by this paper
• Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data.

  1989influential reference
• Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

  1989cited by this paper
• Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

  1989influential reference
• Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.

  1988cited by this paper
• Antitumor activity of l-OHP in mice.

  1985cited by this paper
• Reporting results of cancer treatment

  1981influential reference

• ADAM15 Is a Potential Biomarker for Pan‐Cancer Prognosis and Immunotherapy: Validation in HCC and COAD

  2026cites this paper
• Theranostic Applications of Tailored Lipid-based Nanoparticles as Drug Delivery Systems for Cancer Treatment

  2025cites this paper
• Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis

  2025cites this paper
• Reshaping tumor immune microenvironment and modulating T cell function based on hierarchical nanotherapeutics for synergistically inhibiting osteosarcoma

  2025cites this paper
• Combination therapies and novel delivery systems: a new frontier in overcoming TRAIL resistance in gastric cancer

  2025cites this paper
• Platinum‐Based Chemotherapeutics in the Modern Era: From Classical DNA‐Targeting Mechanisms to Next‐Generation Innovations in Cancer Therapy

  2025cites this paper
• Targeted Nanoparticles: the Smart Way for the Treatment of Colorectal Cancer

  2024cites this paper
• Treatment of stage IV colorectal cancer: A retrospective cohort study assessing whether failure of first‑line treatment indicates failure of second‑line treatment

  2024influential citation
• Ultrasound-Triggered Nanogel Boosts Chemotherapy and Immunomodulation in Colorectal Cancer

  2024cites this paper
• Exosomal circular RNAs in tumor microenvironment: An emphasis on signaling pathways and clinical opportunities

  2024cites this paper
• Pt(iv) derivatives of cisplatin and oxaliplatin bearing an EMT-related TMEM16A/COX-2-selective dual inhibitor against colorectal cancer cells HCT116.

  2024cites this paper
• Protective effect of alpha‐lipoic acid and epalrestat on oxaliplatin‐induced peripheral neuropathy in zebrafish

  2024cites this paper
• Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold

  2024cites this paper
• XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer

  2023cites this paper
• Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies

  2023cites this paper
• Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations

  2023cites this paper
• Nanocarriers for platinum drug delivery

  2023cites this paper
• Finding Focal Adhesion Kinase Inhibitors from Indian Medicinal Plants for Colorectal Cancer- An In-silico Approach

  2023cites this paper
• Recent Advances in RNA m6A Modification in Solid Tumors and Tumor Immunity.

  2023cites this paper
• Quantum mechanical approaches and molecular docking studies of metal based anticancer drugs cis-Diammine glycolato platinum and Diaminocyclohexane oxalatoplatinum structures

  2023cites this paper
• Phototherapeutic anticancer strategies with first-row transition metal complexes: a critical review.

  2022cites this paper
• Nanocarrier System for Increasing the Therapeutic Efficacy of Oxaliplatin.

  2022cites this paper
• Manajemen Kanker Kolorektal

  2022cites this paper
• Highlighting Recent Crystalline Engineering Aspects of Luminescent Coordination Polymers Based on F-Elements and Ditopic Aliphatic Ligands

  2022cites this paper
• Synthesis and Characterization of Ruthenium Complexes and Their Potential and Photosensitizers for Photodynamic Therapy

  2022cites this paper
• Oxaliplatin inhibits colorectal cancer progression by inhibiting CXCL11 secreted by cancer-associated fibroblasts and the CXCR3/PI3K/AKT pathway

  2022cites this paper
• Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin

  2022cites this paper
• Clinical Evidence of Interaction Between Nutraceutical Supplementation and Platinum-based Chemotherapy.

  2022cites this paper
• Evaluation of DNA/BSA interaction and in vitro cell cytotoxicity of μ2-oxido bridged divanadium(V) complexes containing ONO donor ligands.

  2022cites this paper
• Oxaliplatin-flavone pharmaceutical co-crystal-CN111205332A: patent spotlight.

  2022cites this paper
• Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer

  2022cites this paper
• Antiproliferative Activity of Aminobenzylnaphthols Deriving from the Betti Reaction

  2022cites this paper
• Transcriptomic Analysis Identifies Complement Component 3 as a Potential Predictive Biomarker for Chemotherapy Resistance in Colorectal Cancer

  2021cites this paper
• Conventional Chemotherapy Nephrotoxicity.

  2021cites this paper
• Oxaliplatin-Induced Neuropathy: Genetic and Epigenetic Profile to Better Understand How to Ameliorate This Side Effect

  2021cites this paper
• A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling

  2021cites this paper
• Nanomedicines in the treatment of colon cancer: a focus on metallodrugs

  2021cites this paper
• Converting an Almost Noncytotoxic Ru(II) Complex with Photolabile Ligands into a Highly Efficient PACT Agent

  2021cites this paper
• Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS

  2021cites this paper
• In-vitro evaluation of dendrimeric formulation of oxaliplatin

  2021cites this paper
• Reestablishment of Redox Homeostasis in the Nociceptive Primary Afferent as a Mechanism of Antinociception Promoted by Mesenchymal Stem/Stromal Cells in Oxaliplatin-Induced Chronic Peripheral Neuropathy

  2021cites this paper
• MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma

  2020cites this paper
• The hyperpolarization-activated cyclic nucleotide-gated channel currents contribute to oxaliplatin-induced hyperexcitability of DRG neurons

  2020cites this paper
• MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.

  2020cites this paper
• 99mTc-labelled and pH-awakened microbeads entrapping surface-modified lipid nanoparticles for the augmented effect of oxaliplatin in the therapy of colorectal cancer

  2020cites this paper
• Exploration of synthesis, structural aspects, DFT studies and bio-efficacy of some new DHA-benzohydrazide based copper(II) complexes

  2020cites this paper
• Novel nickel(II), palladium(II), and platinum(II) complexes having a pyrrolyl-iminophosphine (PNN) pincer: Synthesis, crystal structures, and cytotoxic activity.

  2020cites this paper
• Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer

  2020cites this paper
• GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.

  2020cites this paper
• Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy

  2020cites this paper
• A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.

  2019cites this paper
• Design, Synthesis, and Anticancer Effect Studies of Iridium(III) Polypyridyl Complexes against SGC-7901 Cells

  2019cites this paper
• Combined olaparib and oxaliplatin inhibits tumor proliferation by cell cycle arrest and cell apoptosis in XRCC2-defecient colorectal cancer

  2019cites this paper
• Cyclophilin B induces chemoresistance by degrading wild‐type p53 via interaction with MDM2 in colorectal cancer

  2018cites this paper
• Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: preparation, optimization, and in vitro evaluation

  2018cites this paper
• Protective effects of Vitis vinifera (grapes) and one of its biologically active constituents, resveratrol, against natural and chemical toxicities: A comprehensive review

  2018cites this paper
• Cyclophilin B induces chemoresistance by degrading wild type p 53 via interaction with MDM 2 in colorectal cancer Running title : Cyclophilin B in CRC chemoresistance

  2018cites this paper
• FORMULATION OF ALBUMIN NANOPARTICLES CONTAINING AN ANTICANCER DRUG OXALIPLATIN

  2018cites this paper
• Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line

  2018cites this paper
• Antiallodynic and antihyperalgesic activity of new 3,3‐diphenyl‐propionamides with anticonvulsant activity in models of pain in mice

  2018cites this paper
• Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.

  2018cites this paper
• Factors associated with the development and severity of oxaliplatin‐induced peripheral neuropathy: a systematic review

  2017cites this paper
• Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin‐based chemotherapy in patients with metastatic colorectal cancer

  2017cites this paper
• Colorectal Carcinogenic Pathways and Chemotherapeutic Responsiveness : A Review

  2017cites this paper
• DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing.

  2017cites this paper
• Upregulation of CX3CL1 mediated by NF-κB activation in dorsal root ganglion contributes to peripheral sensitization and chronic pain induced by oxaliplatin administration

  2017cites this paper
• Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min.

  2016cites this paper
• Altered Expression of Cytoskeletal and Axonal Proteins in Oxaliplatin-Induced Neuropathy

  2016cites this paper
• Polysaccharide from Lentinus edodes combined with oxaliplatin possesses the synergy and attenuation effect in hepatocellular carcinoma.

  2016cites this paper
• Effect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC-7901 cells

  2016cites this paper
• Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma

  2016cites this paper
• Anticonvulsant and antinociceptive activity of new amides derived from 3-phenyl-2,5-dioxo-pyrrolidine-1-yl-acetic acid in mice.

  2016cites this paper
• Trial watch – inhibiting PARP enzymes for anticancer therapy

  2016cites this paper
• Preparation of Oxaliplatin-Deoxycholic Acid Derivative Nanocomplexes and In Vivo Evaluation of Their Oral Absorption and Tumor Growth Suppression.

  2016cites this paper
• Oxaliplatin-induced immune-mediated cytopenias: A case report and literature review

  2015cites this paper
• Discovery and validation of podocalyxin-like protein as a prognostic biomarker in colorectal cancer

  2015cites this paper
• Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and

  2014cites this paper
• Chloroquine and hydroxychloroquine for cancer therapy

  2014cites this paper
• DNA binders in clinical trials and chemotherapy.

  2014cites this paper
• Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice

  2014cites this paper
• Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells

  2014cites this paper
• Oxaliplatin-chitosan nanoparticles induced intrinsic apoptotic signaling pathway: a "smart" drug delivery system to breast cancer cell therapy.

  2014cites this paper
• A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer: A Prospective, Multicenter Trial of the Korean Cancer Study Group

  2014cites this paper
• Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients

  2014cites this paper
• Effects of pH on Oxaliplatin-Induced Condensation of Single DNA Molecules

  2014cites this paper
• Adjuvant Treatment in Colorectal Cancer

  2014cites this paper
• Nanocarriers for delivery of platinum anticancer drugs.

  2013cites this paper
• Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery

  2013cites this paper
• Investigating the genetics and pharmacogenetics of bowel cancer

  2013cites this paper
• Colon cancer therapy: recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs.

  2013cites this paper
• Oxaliplatin and Its Enantiomer Induce Different Condensation Dynamics of Single DNA Molecules

  2013cites this paper
• Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases

  2013cites this paper
• Folfox4 as a rescue chemotherapy for gemcitabine-refractory pancreatic cancer.

  2013cites this paper
• FOLFOX-4 Regimen or Single-agent Gemcitabine as First-line Chemotherapy in Advanced Biliary Tract Cancer

  2013cites this paper
• Su1015 Transient Severe Hyperbilirubinemia After Hepatic Arterial Infusion of Oxaliplatin in Patients With Liver Metastases

  2013cites this paper
• Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin‐induced sensory neuropathy in gastrointestinal cancers

  2013cites this paper
• Oxaliplatin-Induced Leukocytoclastic Vasculitis under Adjuvant Chemotherapy for Colorectal Cancer: Two Cases of a Rare Adverse Event

  2013cites this paper
• Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model.

  2012cites this paper
• Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer

  2012cites this paper
• Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis.

  2012cites this paper